# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Keybanc analyst Brett Fishbin maintains Inspire Medical Systems (NYSE:INSP) with a Overweight and lowers the price target fr...
RBC Capital analyst Shagun Singh reiterates Inspire Medical Systems (NYSE:INSP) with a Outperform and maintains $260 price t...
Baird analyst Mike Polark maintains Inspire Medical Systems (NYSE:INSP) with a Outperform and lowers the price target from $...
Inspire Medical Systems (NYSE:INSP) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of...
Updated Full Year 2024 Revenue Guidance Revenue for full year 2024 is anticipated to be in the range of $788 million to $798...